1. Home
  2. HEPA vs UPC Comparison

HEPA vs UPC Comparison

Compare HEPA & UPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HEPA
  • UPC
  • Stock Information
  • Founded
  • HEPA 2013
  • UPC 1998
  • Country
  • HEPA United States
  • UPC China
  • Employees
  • HEPA N/A
  • UPC 225
  • Industry
  • HEPA Biotechnology: Pharmaceutical Preparations
  • UPC Biotechnology: Pharmaceutical Preparations
  • Sector
  • HEPA Health Care
  • UPC Health Care
  • Exchange
  • HEPA Nasdaq
  • UPC Nasdaq
  • Market Cap
  • HEPA 1.7M
  • UPC 1.5M
  • IPO Year
  • HEPA N/A
  • UPC 2021
  • Fundamental
  • Price
  • HEPA $0.17
  • UPC $0.20
  • Analyst Decision
  • HEPA
  • UPC
  • Analyst Count
  • HEPA 0
  • UPC 0
  • Target Price
  • HEPA N/A
  • UPC N/A
  • AVG Volume (30 Days)
  • HEPA 31.4M
  • UPC 803.8K
  • Earning Date
  • HEPA 04-15-2025
  • UPC 01-01-0001
  • Dividend Yield
  • HEPA N/A
  • UPC N/A
  • EPS Growth
  • HEPA N/A
  • UPC N/A
  • EPS
  • HEPA N/A
  • UPC N/A
  • Revenue
  • HEPA N/A
  • UPC $26,725,919.00
  • Revenue This Year
  • HEPA N/A
  • UPC N/A
  • Revenue Next Year
  • HEPA N/A
  • UPC N/A
  • P/E Ratio
  • HEPA N/A
  • UPC N/A
  • Revenue Growth
  • HEPA N/A
  • UPC N/A
  • 52 Week Low
  • HEPA $0.12
  • UPC $0.12
  • 52 Week High
  • HEPA $3.33
  • UPC $4.32
  • Technical
  • Relative Strength Index (RSI)
  • HEPA 36.41
  • UPC 33.30
  • Support Level
  • HEPA $0.17
  • UPC $0.16
  • Resistance Level
  • HEPA $0.19
  • UPC $0.21
  • Average True Range (ATR)
  • HEPA 0.02
  • UPC 0.04
  • MACD
  • HEPA 0.01
  • UPC 0.03
  • Stochastic Oscillator
  • HEPA 28.55
  • UPC 20.13

About HEPA Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

About UPC Universe Pharmaceuticals Inc.

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

Share on Social Networks: